[1] [3] Current evidence suggests that dulaglutide and extended-release formulations generally demonstrate lower rates of nausea compared to twice-daily exenatide or higher doses of semaglutide and liraglutide used for weight management, though individual responses vary considerably
Recent studies found that while some patients experience positive mental health outcomes, others may need additional support
After building up significant mental preparation, the actual physical sensation frequently registers as minor or barely noticeable
Serious risks, including kidney strain, liver issues, allergic reactions, and rare cases of Stevens-Johnson syndrome, are linked to high doses, counterfeit vials, and unsupervised administration
Pancreatitis is a known risk